IDEAS home Printed from https://ideas.repec.org/e/pep15.html
   My authors  Follow this author

David Mark Epstein

Personal Details

First Name:David
Middle Name:Mark
Last Name:Epstein
Suffix:
RePEc Short-ID:pep15
[This author has chosen not to make the email address public]
http://www.ugr.es/davidepstein
University of Granada Department of Applied Economics

Affiliation

Departamento de Economía Aplicada
Facultad de Ciencias Económicas y Empresariales
Universidad de Granada

Granada, Spain
http://www.ugr.es/~ecoapli/
RePEc:edi:daugres (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. David Epstein, 2016. "Health Related Quality of Life after Surgical Repair of Asymptomatic Abdominal Aortic Aneurysms," FEG Working Paper Series 02/16, Faculty of Economics and Business (University of Granada).
  2. David Epstein & Sarah Onida & Roshan Bootun & Marta Ortega-Ortega & Alun Davies, 2016. "Effectiveness of treatments of varicose veins. Systematic review and evidence synthesis," FEG Working Paper Series 01/16, Faculty of Economics and Business (University of Granada).
  3. David Epstein & Dolores Jimenez-Rubio & Peter C Smith & Marc Suhrcke, 2009. "An economic framework for analysing the social determinants of health and health inequalities," Working Papers 052cherp, Centre for Health Economics, University of York.
  4. Claire McKenna & Zaid Chalabi & David Epstein & Karl Claxton, 2008. "Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions," Working Papers 044cherp, Centre for Health Economics, University of York.

Articles

  1. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2021. "Correction to: A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 847-847, July.
  2. Daniel Pérez-Troncoso & David M. Epstein & José A. Castañeda-García, 2021. "Consumers' Preferences and Willingness to Pay for Personalised Nutrition," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 757-767, September.
  3. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2020. "A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 529-542, June.
  4. David Epstein, 2019. "Beyond the cost‐effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 28(6), pages 801-807, June.
  5. Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher, 2017. "Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 109-123, February.
  6. Edmund Jones & David Epstein & Leticia García-Mochón, 2017. "A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models," Medical Decision Making, , vol. 37(7), pages 779-789, October.
  7. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.
  8. David Epstein & Antonio Olry Labry Lima & Leticia García Mochón & Jaime Espín Balbino & Javier Esquivias, 2014. "A comparison of the accuracy of liquid cytology versus conventional screening: a meta-analysis of split-sample studies," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 177(1), pages 153-168, January.
  9. David Epstein, 2014. "Comment On ‘Heterogeneity In Action: The Role Of Passive Personalization In Comparative Effectiveness Research’," Health Economics, John Wiley & Sons, Ltd., vol. 23(3), pages 374-375, March.
  10. Rita Faria & Manuel Gomes & David Epstein & Ian White, 2014. "A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials," PharmacoEconomics, Springer, vol. 32(12), pages 1157-1170, December.
  11. David Epstein & Leticia García Mochón & Jaime Espín & Marta O. Soares, 2013. "Use of Multiparameter Evidence Synthesis to Assess the Appropriateness of Data and Structure in Decision Models," Medical Decision Making, , vol. 33(5), pages 715-730, July.
  12. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.
  13. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
  14. David Epstein & Dolores Jiménez‐Rubio & Peter C. Smith & Marc Suhrcke, 2009. "Social determinants of health: an economic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 495-502, May.
  15. David Epstein & Anne Mason & Andrea Manca, 2008. "The hospital costs of care for stroke in nine European countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 21-31, January.
  16. Chalabi, Zaid & Epstein, David & McKenna, Claire & Claxton, Karl, 2008. "Uncertainty and value of information when allocating resources within and between healthcare programmes," European Journal of Operational Research, Elsevier, vol. 191(2), pages 530-539, December.
  17. David M. Epstein & Zaid Chalabi & Karl Claxton & Mark Sculpher, 2007. "Efficiency, Equity, and Budgetary Policies," Medical Decision Making, , vol. 27(2), pages 128-137, March.
  18. David Epstein & Anne Mason, 2006. "Costs and prices for inpatient care in England: Mirror twins or distant cousins?," Health Care Management Science, Springer, vol. 9(3), pages 233-242, August.
  19. Neil Hawkins & David Epstein & Michael Drummond & Jennifer Wilby & Anita Kainth & David Chadwick & Mark Sculpher, 2005. "Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model," Medical Decision Making, , vol. 25(5), pages 493-510, September.
  20. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Claire McKenna & Zaid Chalabi & David Epstein & Karl Claxton, 2008. "Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions," Working Papers 044cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Afschin Gandjour, 2015. "A model to optimize investments in health technologies, quality of care and research," Applied Economics, Taylor & Francis Journals, vol. 47(20), pages 2031-2039, April.
    2. Martin Forster & Paolo Pertile, 2013. "Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(12), pages 1507-1514, December.
    3. Michael Fairley & Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert, 2020. "Optimal Allocation of Research Funds under a Budget Constraint," Medical Decision Making, , vol. 40(6), pages 797-814, August.
    4. Lahav, Yael & Herbon, Avi & Spiegel, Uriel, 2023. "The cost-benefit approach to an optimal charging scheme for an embryo storage service," Operations Research Perspectives, Elsevier, vol. 10(C).
    5. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    6. H. Koffijberg & G. A. de Wit & T. L. Feenstra, 2012. "Communicating Uncertainty in Economic Evaluations," Medical Decision Making, , vol. 32(3), pages 477-487, May.
    7. Tom L. Drake & Yoel Lubell & Shwe Sin Kyaw & Angela Devine & Myat Phone Kyaw & Nicholas P. J. Day & Frank M. Smithuis & Lisa J. White, 2017. "Geographic Resource Allocation Based on Cost Effectiveness: An Application to Malaria Policy," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 299-306, June.
    8. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
    9. Kurth, Margaret & Keisler, Jeffrey M. & Bates, Matthew E. & Bridges, Todd S. & Summers, Jeffrey & Linkov, Igor, 2017. "A portfolio decision analysis approach to support energy research and development resource allocation," Energy Policy, Elsevier, vol. 105(C), pages 128-135.
    10. Nadia Demarteau & Thomas Breuer & Baudouin Standaert, 2012. "Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program," PharmacoEconomics, Springer, vol. 30(4), pages 337-353, April.

Articles

  1. Daniel Pérez-Troncoso & David M. Epstein & José A. Castañeda-García, 2021. "Consumers' Preferences and Willingness to Pay for Personalised Nutrition," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 757-767, September.

    Cited by:

    1. Pérez-Troncoso, Daniel, 2022. "Optimal sequential strategy to improve the precision of the estimators in a discrete choice experiment: A simulation study," Journal of choice modelling, Elsevier, vol. 43(C).

  2. Zuzana Špacírová & David Epstein & Leticia García-Mochón & Joan Rovira & Antonio Olry de Labry Lima & Jaime Espín, 2020. "A general framework for classifying costing methods for economic evaluation of health care," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 529-542, June.

    Cited by:

    1. Candio, Paolo & Meads, David & Hill, Andrew J. & Bojke, Laura, 2021. "Taking a local government perspective for economic evaluation of a population-level programme to promote exercise," Health Policy, Elsevier, vol. 125(5), pages 651-657.
    2. Brahim Bouyahyaoui & Naji Saida & Youssef Hafidi, 2022. "Costs associated with using pharmaceuticals for breast cancer treatment at the Hassan II University Hospital in Fez, Morocco : an ABC method trial [Coût de la consommation des produits pharmaceutiq," Post-Print hal-03993420, HAL.
    3. Leticia García-Mochón & Zuzana Špacírová & Jaime Espín, 2022. "Costing methodologies in European economic evaluation guidelines: commonalities and divergences," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(6), pages 979-991, August.
    4. Zuzana Špacírová & David Epstein & Jaime Espín, 2022. "Are costs derived from diagnosis-related groups suitable for use in economic evaluations? A comparison across nine European countries in the European Healthcare and Social Cost Database," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1563-1575, December.

  3. Claire Rothery & Karl Claxton & Stephen Palmer & David Epstein & Rosanna Tarricone & Mark Sculpher, 2017. "Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 109-123, February.

    Cited by:

    1. Tarricone, Rosanna & Amatucci, Fabio & Armeni, Patrizio & Banks, Helen & Borsoi, Ludovica & Callea, Giuditta & Ciani, Oriana & Costa, Francesco & Federici, Carlo & Torbica, Aleksandra & Marletta, Marc, 2021. "Establishing a national HTA program for medical devices in Italy: Overhauling a fragmented system to ensure value and equal access to new medical technologies," Health Policy, Elsevier, vol. 125(5), pages 602-608.
    2. Aleksandra Torbica & Rosanna Tarricone & Jonas Schreyögg & Mike Drummond, 2022. "Pushing the boundaries of evaluation, diffusion, and use of medical devices in Europe: Insights from the COMED project," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 1-9, September.
    3. Michael Drummond & Carlo Federici & Vivian Reckers‐Droog & Aleksandra Torbica & Carl Rudolf Blankart & Oriana Ciani & Zoltán Kaló & Sándor Kovács & Werner Brouwer, 2022. "Coverage with evidence development for medical devices in Europe: Can practice meet theory?," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 179-194, September.
    4. Rosanna Tarricone & Aleksandra Torbica & Michael Drummond & for the MedtecHTA Project Group, 2017. "Key Recommendations from the MedtecHTA Project," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 145-152, February.
    5. Sandor Kovács & Zoltán Kaló & Rita Daubner‐Bendes & Katarzyna Kolasa & Rok Hren & Tomas Tesar & Vivian Reckers‐Droog & Werner Brouwer & Carlo Federici & Mike Drummond & Antal Tamás Zemplényi, 2022. "Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 195-206, September.
    6. Rosanna Tarricone & Aleksandra Torbica & Michael Drummond, 2017. "Challenges in the Assessment of Medical Devices: The MedtecHTA Project," Health Economics, John Wiley & Sons, Ltd., vol. 26(S1), pages 5-12, February.

  4. Edmund Jones & David Epstein & Leticia García-Mochón, 2017. "A Procedure for Deriving Formulas to Convert Transition Rates to Probabilities for Multistate Markov Models," Medical Decision Making, , vol. 37(7), pages 779-789, October.

    Cited by:

    1. Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Es, 2023. "The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1033-1045, September.

  5. David Epstein & Leticia García-Mochón & Stephen Kaptoge & Simon G. Thompson, 2016. "Modeling the costs and long-term health benefits of screening the general population for risks of cardiovascular disease: a review of methods used in the literature," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1041-1053, November.

    Cited by:

    1. Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Es, 2023. "The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1033-1045, September.

  6. Rita Faria & Manuel Gomes & David Epstein & Ian White, 2014. "A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials," PharmacoEconomics, Springer, vol. 32(12), pages 1157-1170, December.

    Cited by:

    1. Victoria K. Brennan & Georgina Jones & Stephen Radley & Simon Dixon, 2021. "Incorporating Process Utility into Cost-Effectiveness Analysis via a Bolt-On Domain to the SF-6D: An Exploratory Study," Applied Health Economics and Health Policy, Springer, vol. 19(5), pages 747-756, September.
    2. Rissanen, Elisa & Karjalainen, Piia & Kiviruusu, Olli & Kankaanpää, Eila & Aronen, Eeva T. & Haula, Taru & Sääksvuori, Lauri & Vornanen, Riitta & Linnosmaa, Ismo, 2024. "Cost-effectiveness of a parenting program to reduce children’s behavioral problems among families receiving child protection services and other family support services – A randomized controlled trial," Children and Youth Services Review, Elsevier, vol. 158(C).
    3. Benjamin Thorpe & Orlagh Carroll & Linda Sharples, 2018. "Methods for Handling Unobserved Covariates in a Bayesian Update of a Cost-effectiveness Model," Medical Decision Making, , vol. 38(2), pages 150-162, February.
    4. Ifigeneia Mavranezouli & Joran Lokkerbol, 2017. "A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder," PharmacoEconomics, Springer, vol. 35(3), pages 271-296, March.
    5. Laura Pirhonen & Kristian Bolin & Elisabeth Hansson Olofsson & Andreas Fors & Inger Ekman & Karl Swedberg & Hanna Gyllensten, 2019. "Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial," PharmacoEconomics - Open, Springer, vol. 3(4), pages 495-504, December.
    6. Andrea Gabrio & Catrin Plumpton & Sube Banerjee & Baptiste Leurent, 2022. "Linear mixed models to handle missing at random data in trial‐based economic evaluations," Health Economics, John Wiley & Sons, Ltd., vol. 31(6), pages 1276-1287, June.
    7. Emma A. Nieuwenhuijse & Rimke C. Vos & Wilbert B. van den Hout & Jeroen N. Struijs & Sanne M. Verkleij & Karin Busch & Mattijs E. Numans & Tobias N. Bonten, 2023. "The Effect and Cost-Effectiveness of Offering a Combined Lifestyle Intervention for the Prevention of Cardiovascular Disease in Primary Care: Results of the Healthy Heart Stepped-Wedge Trial," IJERPH, MDPI, vol. 20(6), pages 1-17, March.
    8. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    9. Janet MacNeil Vroomen & Judith E Bosmans & Iris Eekhout & Karlijn J Joling & Lisa D van Mierlo & Franka J M Meiland & Hein P J van Hout & Sophia E de Rooij, 2016. "The Cost-Effectiveness of Two Forms of Case Management Compared to a Control Group for Persons with Dementia and Their Informal Caregivers from a Societal Perspective," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-20, September.
    10. Bernhard Michalowsky & Wolfgang Hoffmann & Kevin Kennedy & Feng Xie, 2020. "Is the whole larger than the sum of its parts? Impact of missing data imputation in economic evaluation conducted alongside randomized controlled trials," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 717-728, July.
    11. David Glynn & John Giardina & Julia Hatamyar & Ankur Pandya & Marta Soares & Noemi Kreif, 2024. "Integrating decision modeling and machine learning to inform treatment stratification," Health Economics, John Wiley & Sons, Ltd., vol. 33(8), pages 1772-1792, August.
    12. Ilias Goranitis & Leana Bellanca & Amanda J Daley & Adele Thomas & Helen Stokes-Lampard & Andrea K Roalfe & Sue Jowett, 2017. "Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial," PLOS ONE, Public Library of Science, vol. 12(9), pages 1-15, September.
    13. Stephen Rocks & Daniela Berntson & Alejandro Gil-Salmerón & Mudathira Kadu & Nieves Ehrenberg & Viktoria Stein & Apostolos Tsiachristas, 2020. "Cost and effects of integrated care: a systematic literature review and meta-analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1211-1221, November.
    14. Adriano Zanin Zambom & Gregory J. Matthews, 2021. "Sure independence screening in the presence of missing data," Statistical Papers, Springer, vol. 62(2), pages 817-845, April.
    15. Alexina J. Mason & Manuel Gomes & Richard Grieve & James R. Carpenter, 2018. "A Bayesian framework for health economic evaluation in studies with missing data," Health Economics, John Wiley & Sons, Ltd., vol. 27(11), pages 1670-1683, November.
    16. Padraig Dixon & William Hollingworth & Jonathan Benger & James Calvert & Melanie Chalder & Anna King & Stephanie MacNeill & Katherine Morton & Emily Sanderson & Sarah Purdy, 2020. "Observational Cost-Effectiveness Analysis Using Routine Data: Admission and Discharge Care Bundles for Patients with Chronic Obstructive Pulmonary Disease," PharmacoEconomics - Open, Springer, vol. 4(4), pages 657-667, December.
    17. Abualbishr Alshreef & Allan J. Wailoo & Steven R. Brown & James P. Tiernan & Angus J. M. Watson & Katie Biggs & Mike Bradburn & Daniel Hind, 2017. "Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial," PharmacoEconomics - Open, Springer, vol. 1(3), pages 175-184, September.
    18. Baptiste Leurent & Manuel Gomes & James R. Carpenter, 2018. "Missing data in trial‐based cost‐effectiveness analysis: An incomplete journey," Health Economics, John Wiley & Sons, Ltd., vol. 27(6), pages 1024-1040, June.
    19. Jackie, Yenerall & Wen, You & George, Davis & Paul, Estabrooks, 2015. "Examining Ways to Handle Non-Random Missingness in CEA through Econometric and Statistics Lenses," 2015 AAEA & WAEA Joint Annual Meeting, July 26-28, San Francisco, California 205690, Agricultural and Applied Economics Association.
    20. Janet MacNeil Vroomen & Iris Eekhout & Marcel G. Dijkgraaf & Hein van Hout & Sophia E. de Rooij & Martijn W. Heymans & Judith E. Bosmans, 2016. "Multiple imputation strategies for zero-inflated cost data in economic evaluations: which method works best?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 939-950, November.
    21. Sun Sun & Nan Luo & Erik Stenberg & Lars Lindholm & Klas-Göran Sahlén & Karl A. Franklin & Yang Cao, 2022. "Sequential Multiple Imputation for Real-World Health-Related Quality of Life Missing Data after Bariatric Surgery," IJERPH, MDPI, vol. 19(17), pages 1-16, August.
    22. Alexina J. Mason & Manuel Gomes & James Carpenter & Richard Grieve, 2021. "Flexible Bayesian longitudinal models for cost‐effectiveness analyses with informative missing data," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3138-3158, December.
    23. Jacqueline J Suijker & Janet L MacNeil-Vroomen & Marjon van Rijn & Bianca M Buurman & Sophia E de Rooij & Eric P Moll van Charante & Judith E Bosmans, 2017. "Cost-effectiveness of nurse-led multifactorial care to prevent or postpone new disabilities in community-living older people: Results of a cluster randomized trial," PLOS ONE, Public Library of Science, vol. 12(4), pages 1-16, April.
    24. William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis, 2020. "Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT," PharmacoEconomics - Open, Springer, vol. 4(3), pages 427-438, September.
    25. Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter, 2018. "Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial," PharmacoEconomics, Springer, vol. 36(8), pages 889-901, August.
    26. Baptiste Leurent & Manuel Gomes & Suzie Cro & Nicola Wiles & James R. Carpenter, 2020. "Reference‐based multiple imputation for missing data sensitivity analyses in trial‐based cost‐effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 29(2), pages 171-184, February.
    27. Andrea Gabrio & Alexina J. Mason & Gianluca Baio, 2017. "Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations," PharmacoEconomics - Open, Springer, vol. 1(2), pages 79-97, June.
    28. Ângela Jornada Ben & Johanna M. Dongen & Mohamed El Alili & Martijn W. Heymans & Jos W. R. Twisk & Janet L. MacNeil-Vroomen & Maartje Wit & Susan E. M. Dijk & Teddy Oosterhuis & Judith E. Bosmans, 2023. "The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 951-965, August.
    29. Mohamed El Alili & Johanna M. van Dongen & Jonas L. Esser & Martijn W. Heymans & Maurits W. van Tulder & Judith E. Bosmans, 2022. "A scoping review of statistical methods for trial‐based economic evaluations: The current state of play," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2680-2699, December.
    30. Helen A. Dakin & José Leal & Andrew Briggs & Philip Clarke & Rury R. Holman & Alastair Gray, 2020. "Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data," Medical Decision Making, , vol. 40(4), pages 460-473, May.
    31. Becky Pennington & Abualbishr Alshreef & Laura Flight & Andrew Metry & Edith Poku & Philip Hykin & Sobha Sivaprasad & A. Toby Prevost & Joana C. Vasconcelos & Caroline Murphy & Joanna Kelly & Yit Yang, 2021. "Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study," PharmacoEconomics, Springer, vol. 39(8), pages 913-927, August.
    32. David M. Meads & Adam Martin & Alys Griffiths & Rachael Kelley & Byron Creese & Louise Robinson & Joanne McDermid & Rebecca Walwyn & Clive Ballard & Claire A. Surr, 2020. "Cost-Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a Randomised Controlled Trial," Applied Health Economics and Health Policy, Springer, vol. 18(2), pages 237-247, April.

  7. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.

    Cited by:

    1. Eldon Spackman & Stephen Rice & Gill Norman & Dong-Churl Suh & Alison Eastwood & Stephen Palmer, 2013. "Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer," PharmacoEconomics, Springer, vol. 31(3), pages 185-194, March.
    2. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    3. E. Simpson & P. Fitzgerald & P. Evans & P. Tappenden & N. Kalita & J. Reckless & A. Bakhai, 2013. "Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(4), pages 269-275, April.
    4. Jonathan Tosh & Rachel Archer & Sarah Davis & Matt Stevenson & John Stevens, 2013. "Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(8), pages 653-661, August.
    5. Eleftherios Sideris & Mark Corbett & Stephen Palmer & Nerys Woolacott & Laura Bojke, 2016. "The Clinical and Cost Effectiveness of Apremilast for Treating Active Psoriatic Arthritis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(11), pages 1101-1110, November.
    6. Bernd Schweikert & Chiara Malmberg & Örjan Åkerborg & Gayathri Kumar & Debby Nott & Sandeep Kiri & Christophe Sapin & Susanne Hartz, 2020. "Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK," PharmacoEconomics - Open, Springer, vol. 4(4), pages 635-648, December.
    7. Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson, 2013. "Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(11), pages 981-990, November.
    8. Rita Faria & Eldon Spackman & Jane Burch & Belen Corbacho & Derick Todd & Chris Pepper & Nerys Woolacott & Stephen Palmer, 2013. "Dabigatran for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(7), pages 551-562, July.
    9. Ben Kearns & Myfanwy Lloyd Jones & Matt Stevenson & Chris Littlewood, 2013. "Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(6), pages 479-488, June.
    10. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    11. Afschin Gandjour & Dennis A. Ostwald, 2020. "Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 109-125, February.
    12. Karen Smith & Su Golder & Abeed Sarker & Yoon Loke & Karen O’Connor & Graciela Gonzalez-Hernandez, 2018. "Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab," Drug Safety, Springer, vol. 41(12), pages 1397-1410, December.
    13. Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012. "Bevacizumab for Metastatic Colorectal Cancer," PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
    14. Joanne O’Connor & Stephen Rice & Alison Smith & Mark Rodgers & Rocio Rodriguez Lopez & Dawn Craig & Nerys Woolacott, 2016. "The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(4), pages 337-348, April.
    15. Sophie Whyte & Abdullah Pandor & Matt Stevenson, 2012. "Bevacizumab for Metastatic Colorectal Cancer," PharmacoEconomics, Springer, vol. 30(12), pages 1119-1132, December.
    16. Nigel Armstrong & Manuela Joore & Thea Asselt & Kate Misso & Nathan Manning & Florian Tomini & Jos Kleijnen & Rob Riemsma, 2013. "Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(5), pages 415-425, May.
    17. Dawn Craig & Stephen Rice & Fiona Paton & David Fox & Nerys Woolacott, 2013. "Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization," PharmacoEconomics, Springer, vol. 31(2), pages 101-110, February.
    18. Laura Bojke & Andrea Manca & Miqdad Asaria & Ronan Mahon & Shijie Ren & Stephen Palmer, 2017. "How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 767-776, August.
    19. Janette Greenhalgh & Adrian Bagust & Angela Boland & Michaela Blundell & James Oyee & Sophie Beale & Yenal Dundar & Juliet Hockenhull & Chris Proudlove & Patrick Chu, 2013. "Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma," PharmacoEconomics, Springer, vol. 31(5), pages 403-413, May.
    20. Mary Kilonzo & Jenni Hislop & Andrew Elders & Cynthia Fraser & Donald Bissett & Samuel McClinton & Graham Mowatt & Luke Vale, 2013. "Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma," PharmacoEconomics, Springer, vol. 31(1), pages 15-24, January.
    21. Rachid Rafia & Emma Simpson & Matt Stevenson & Diana Papaioannou, 2013. "Trabectedin for the Treatment of Advanced Metastatic Soft Tissue Sarcoma: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(6), pages 471-478, June.
    22. Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani, 2014. "Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 32(12), pages 1171-1183, December.

  8. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    See citations under working paper version above.
  9. David Epstein & Dolores Jiménez‐Rubio & Peter C. Smith & Marc Suhrcke, 2009. "Social determinants of health: an economic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 18(5), pages 495-502, May.

    Cited by:

    1. Grace Lordan & Eliana Jimenez Soto & Richard P. C. Brown & Ignacio Correa‐Valez, 2012. "Socioeconomic status and health outcomes in a developing country," Health Economics, John Wiley & Sons, Ltd., vol. 21(2), pages 178-186, February.
    2. Bridget O'Laughlin & Bridget O'Laughlin, 2016. "Forum 2016," Development and Change, International Institute of Social Studies, vol. 47(4), pages 686-711, July.
    3. Costa Font, Joan & Hernández-Quevedo, Cristina & McGuire, Alistair, 2011. "Persistence despite action? Measuring the patterns of health inequality in England (1997–2007)," Health Policy, Elsevier, vol. 103(2), pages 149-159.
    4. Angell, Blake & Cullen, Patricia & Laba, Tracey & Lung, Tom & Shanahan, Marian & Sakashita, Chika & Eades, Sandra & Ivers, Rebecca & Jan, Stephen, 2018. "What is the value of a driver licence? A contingent valuation study of Australian adults," Transportation Research Part A: Policy and Practice, Elsevier, vol. 108(C), pages 25-34.
    5. Sandy Tubeuf & Florence Jusot, 2011. "Social health inequalities among older Europeans: the contribution of social and family background," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(1), pages 61-77, February.
    6. Morton, Alec, 2014. "Aversion to health inequalities in healthcare prioritisation: A multicriteria optimisation perspective," Journal of Health Economics, Elsevier, vol. 36(C), pages 164-173.
    7. Pega, Frank & Valentine, Nicole B. & Matheson, Don & Rasanathan, Kumanan, 2014. "Public social monitoring reports and their effect on a policy programme aimed at addressing the social determinants of health to improve health equity in New Zealand," Social Science & Medicine, Elsevier, vol. 101(C), pages 61-69.

  10. David Epstein & Anne Mason & Andrea Manca, 2008. "The hospital costs of care for stroke in nine European countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 21-31, January.

    Cited by:

    1. Brenna Ellison & Jayson L Lusk, 2018. "Examining Household Food Waste Decisions: A Vignette Approach," Applied Economic Perspectives and Policy, John Wiley & Sons, vol. 40(4), pages 613-631, December.
    2. M. Pirson & L. Schenker & D. Martins & Duong Dung & J. Chalé & P. Leclercq, 2013. "What can we learn from international comparisons of costs by DRG?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 67-73, February.
    3. Raymond Oppong & Joanna Coast & Kerry Hood & Jacqui Nuttall & Richard Smith & Christopher Butler, 2011. "Resource use and costs of treating acute cough/lower respiratory tract infections in 13 European countries: results and challenges," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(4), pages 319-329, August.
    4. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross‐country comparisons of costs: the use of episode‐specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103, January.
    5. Reinhard Busse & Jonas Schreyögg & Peter C. Smith, 2008. "Variability in healthcare treatment costs amongst nine EU countries – results from the HealthBASKET project," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 1-8, January.
    6. Reinhard Busse & on behalf of the EuroDRG group, 2012. "DO DIAGNOSIS‐RELATED GROUPS EXPLAIN VARIATIONS IN HOSPITAL COSTS AND LENGTH OF STAY? – ANALYSES FROM THE EURODRG PROJECT FOR 10 EPISODES OF CARE ACROSS 10 EuroPEAN COUNTRIES," Health Economics, John Wiley & Sons, Ltd., vol. 21(S2), pages 1-5, August.
    7. Bystrov, Victor & Staszewska-Bystrova, Anna & Rutkowski, Daniel & Hermanowski, Tomasz, 2015. "Effects of DRG-based hospital payment in Poland on treatment of patients with stroke," Health Policy, Elsevier, vol. 119(8), pages 1119-1125.

  11. Chalabi, Zaid & Epstein, David & McKenna, Claire & Claxton, Karl, 2008. "Uncertainty and value of information when allocating resources within and between healthcare programmes," European Journal of Operational Research, Elsevier, vol. 191(2), pages 530-539, December.

    Cited by:

    1. Galioto, F., 2018. "The value of information for the management of water resources in agriculture: comparing the economic impact of alternative sources of information to schedule irrigation," 2018 Conference, July 28-August 2, 2018, Vancouver, British Columbia 277384, International Association of Agricultural Economists.
    2. Thul, Lawrence & Powell, Warren, 2023. "Stochastic optimization for vaccine and testing kit allocation for the COVID-19 pandemic," European Journal of Operational Research, Elsevier, vol. 304(1), pages 325-338.
    3. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    4. Bayram, Armagan & Solak, Senay & Johnson, Michael, 2014. "Stochastic models for strategic resource allocation in nonprofit foreclosed housing acquisitions," European Journal of Operational Research, Elsevier, vol. 233(1), pages 246-262.
    5. Yiting Xing & Ling Li & Zhuming Bi & Marzena Wilamowska‐Korsak & Li Zhang, 2013. "Operations Research (OR) in Service Industries: A Comprehensive Review," Systems Research and Behavioral Science, Wiley Blackwell, vol. 30(3), pages 300-353, May.
    6. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & Negrín, M.A., 2012. "Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis," European Journal of Operational Research, Elsevier, vol. 218(2), pages 512-522.
    7. Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & NegrI´n, M.A., 2010. "Optimal healthcare decisions: Comparing medical treatments on a cost-effectiveness basis," European Journal of Operational Research, Elsevier, vol. 204(1), pages 180-187, July.
    8. H. Koffijberg & G. A. de Wit & T. L. Feenstra, 2012. "Communicating Uncertainty in Economic Evaluations," Medical Decision Making, , vol. 32(3), pages 477-487, May.
    9. Tom L. Drake & Yoel Lubell & Shwe Sin Kyaw & Angela Devine & Myat Phone Kyaw & Nicholas P. J. Day & Frank M. Smithuis & Lisa J. White, 2017. "Geographic Resource Allocation Based on Cost Effectiveness: An Application to Malaria Policy," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 299-306, June.
    10. Zou, Guang & Faber, Michael Havbro & González, Arturo & Banisoleiman, Kian, 2021. "Computing the value of information from periodic testing in holistic decision making under uncertainty," Reliability Engineering and System Safety, Elsevier, vol. 206(C).
    11. Bozkir, Cem D.C. & Ozmemis, Cagri & Kurbanzade, Ali Kaan & Balcik, Burcu & Gunes, Evrim D. & Tuglular, Serhan, 2023. "Capacity planning for effective cohorting of hemodialysis patients during the coronavirus pandemic: A case study," European Journal of Operational Research, Elsevier, vol. 304(1), pages 276-291.
    12. Cannon, Jeffrey W. & Mueller, Ute A. & Hornbuckle, Janet & Larson, Ann & Simmer, Karen & Newnham, John P. & Doherty, Dorota A., 2013. "Economic implications of poor access to antenatal care in rural and remote Western Australian Aboriginal communities: An individual sampling model of pregnancy," European Journal of Operational Research, Elsevier, vol. 226(2), pages 313-324.

  12. David M. Epstein & Zaid Chalabi & Karl Claxton & Mark Sculpher, 2007. "Efficiency, Equity, and Budgetary Policies," Medical Decision Making, , vol. 27(2), pages 128-137, March.

    Cited by:

    1. Katherine T. Lofgren & David A. Watkins & Solomon T. Memirie & Joshua A. Salomon & Stéphane Verguet, 2021. "Balancing health and financial protection in health benefit package design," Health Economics, John Wiley & Sons, Ltd., vol. 30(12), pages 3236-3247, December.
    2. Monali Malvankar-Mehta & Bin Xie, 2012. "Optimal incentives for allocating HIV/AIDS prevention resources among multiple populations," Health Care Management Science, Springer, vol. 15(4), pages 327-338, December.
    3. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    4. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
    5. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
    6. van Baal, Pieter & Morton, Alec & Severens, Johan L., 2018. "Health care input constraints and cost effectiveness analysis decision rules," Social Science & Medicine, Elsevier, vol. 200(C), pages 59-64.
    7. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
    8. Feenstra, T.L. & van Baal, P.M. & Jacobs-van der Bruggen, M.A.M. & Hoogenveen, R.T. & Kommer, G.J. & Baan, C.A., 2011. "Targeted versus universal prevention. A resource allocation model to prioritize cardiovascular prevention," Other publications TiSEM da2bcf9c-cba4-4f97-86bf-a, Tilburg University, School of Economics and Management.
    9. Morton, Alec & Thomas, Ranjeeta & Smith, Peter C., 2016. "Decision rules for allocation of finances to health systems strengthening," Journal of Health Economics, Elsevier, vol. 49(C), pages 97-108.
    10. Nadia Demarteau & Thomas Breuer & Baudouin Standaert, 2012. "Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program," PharmacoEconomics, Springer, vol. 30(4), pages 337-353, April.
    11. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
    12. Chalabi, Zaid & Epstein, David & McKenna, Claire & Claxton, Karl, 2008. "Uncertainty and value of information when allocating resources within and between healthcare programmes," European Journal of Operational Research, Elsevier, vol. 191(2), pages 530-539, December.
    13. Daniel Howdon & James Lomas, 2017. "Pricing implications of non-marginal budgetary impacts in health technology assessment: a conceptual model," Working Papers 148cherp, Centre for Health Economics, University of York.
    14. Morton, Alec, 2014. "Aversion to health inequalities in healthcare prioritisation: A multicriteria optimisation perspective," Journal of Health Economics, Elsevier, vol. 36(C), pages 164-173.

  13. David Epstein & Anne Mason, 2006. "Costs and prices for inpatient care in England: Mirror twins or distant cousins?," Health Care Management Science, Springer, vol. 9(3), pages 233-242, August.

    Cited by:

    1. Matthias Vogl, 2012. "Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    2. Oliver Tiemann, 2008. "Variations in hospitalisation costs for acute myocardial infarction – a comparison across Europe," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 33-45, January.
    3. Vogl, Matthias, 2013. "Improving patient-level costing in the English and the German ‘DRG’ system," Health Policy, Elsevier, vol. 109(3), pages 290-300.
    4. Andrew Street & Kirsi Vitikainen & Afsaneh Bjorvatn & Anne Hvenegaard, 2007. "Introducing activity-based financing: a review of experience in Australia, Denmark, Norway and Sweden," Working Papers 030cherp, Centre for Health Economics, University of York.
    5. Vogl, Matthias, 2014. "Hospital financing: Calculating inpatient capital costs in Germany with a comparative view on operating costs and the English costing scheme," Health Policy, Elsevier, vol. 115(2), pages 141-151.
    6. Raulinajtys-Grzybek, Monika, 2014. "Cost accounting models used for price-setting of health services: An international review," Health Policy, Elsevier, vol. 118(3), pages 341-353.
    7. Wozny, Florian, 2020. "Hospital Resources: Persistent Reallocation under Price Changes," IZA Discussion Papers 13256, Institute of Labor Economics (IZA).
    8. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann & Reinhard Busse, 2006. "Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries," Health Care Management Science, Springer, vol. 9(3), pages 215-223, August.
    9. Galina Besstremyannaya, 2013. "The impact of Japanese hospital financing reform on hospital efficiency: A difference-in-difference approach," The Japanese Economic Review, Japanese Economic Association, vol. 64(3), pages 337-362, September.
    10. Fainman, Emily Zhu & Kucukyazici, Beste, 2020. "Design of financial incentives and payment schemes in healthcare systems: A review," Socio-Economic Planning Sciences, Elsevier, vol. 72(C).
    11. Polyzos, Nikolaos & Karanikas, Haralampos & Thireos, Eleftherios & Kastanioti, Catherine & Kontodimopoulos, Nick, 2013. "Reforming reimbursement of public hospitals in Greece during the economic crisis: Implementation of a DRG system," Health Policy, Elsevier, vol. 109(1), pages 14-22.

  14. Neil Hawkins & David Epstein & Michael Drummond & Jennifer Wilby & Anita Kainth & David Chadwick & Mark Sculpher, 2005. "Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model," Medical Decision Making, , vol. 25(5), pages 493-510, September.

    Cited by:

    1. John Hornberger & Katherine Robertus, 2005. "Comprehensive Evaluations of Health Care Interventions: The Realism-Transparency Tradeoff," Medical Decision Making, , vol. 25(5), pages 490-492, September.
    2. Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond, 2008. "Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(2), pages 137-145, May.
    3. Steven M. Teutsch & Marc L. Berger, 2005. "Evidence Synthesis and Evidence-Based Decision Making: Related But Distinct Processes," Medical Decision Making, , vol. 25(5), pages 487-489, September.
    4. Neil Hawkins & David A. Scott, 2010. "Cost-Effectiveness Analysis: Discount the Placebo at Your Peril," Medical Decision Making, , vol. 30(5), pages 536-543, September.
    5. Louise B. Russell, 2005. "Comparing Model Structures in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 25(5), pages 485-486, September.

  15. Neil Hawkins & Mark Sculpher & David Epstein, 2005. "Cost-Effectiveness Analysis of Treatments for Chronic Disease: Using R to Incorporate Time Dependency of Treatment Response," Medical Decision Making, , vol. 25(5), pages 511-519, September.

    Cited by:

    1. John Hornberger & Katherine Robertus, 2005. "Comprehensive Evaluations of Health Care Interventions: The Realism-Transparency Tradeoff," Medical Decision Making, , vol. 25(5), pages 490-492, September.
    2. Marta O. Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    3. Marta Soares & Luísa Canto e Castro, 2012. "Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 30(12), pages 1101-1117, December.
    4. Steven M. Teutsch & Marc L. Berger, 2005. "Evidence Synthesis and Evidence-Based Decision Making: Related But Distinct Processes," Medical Decision Making, , vol. 25(5), pages 487-489, September.
    5. Marta O Soares & L Canto e Castro, 2010. "Simulation or cohort models? Continuous time simulation and discretized Markov models to estimate cost-effectiveness," Working Papers 056cherp, Centre for Health Economics, University of York.
    6. Louise B. Russell, 2005. "Comparing Model Structures in Cost-Effectiveness Analysis," Medical Decision Making, , vol. 25(5), pages 485-486, September.
    7. Ruth A. Lewis & Dyfrig Hughes & Alex J. Sutton & Clare Wilkinson, 2021. "Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions," PharmacoEconomics, Springer, vol. 39(1), pages 25-61, January.
    8. Fernando Alarid-Escudero & Eline Krijkamp & Eva A. Enns & Alan Yang & M. G. Myriam Hunink & Petros Pechlivanoglou & Hawre Jalal, 2023. "A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example," Medical Decision Making, , vol. 43(1), pages 21-41, January.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 2 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. NEP-HEA: Health Economics (2) 2009-11-07 2016-12-18

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, David Mark Epstein should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.